The Zhitong Finance App learned that CICC released a research report stating that Kangfang Biotech (09926.HK) announced AK112, with the trade name Idafang. Compared with the registered phase III clinical trial (HARMONI-2) of pabolizumab used in first-line treatment of PD-L1-positive NSCLC (), WCLC announced significant positive OS results. Considering the impressive H2 data, the bank raised the probability of overseas H7 clinical success, kept the 2026 and 2027 profit forecasts unchanged, maintained a “outperforming industry” rating, and raised the target price by 8.3% to HK$130.
Zhitongcaijing · 2d ago
Share
Listen to the news
The Zhitong Finance App learned that CICC released a research report stating that Kangfang Biotech (09926.HK) announced AK112, with the trade name Idafang. Compared with the registered phase III clinical trial (HARMONI-2) of pabolizumab used in first-line treatment of PD-L1-positive NSCLC (), WCLC announced significant positive OS results. Considering the impressive H2 data, the bank raised the probability of overseas H7 clinical success, kept the 2026 and 2027 profit forecasts unchanged, maintained a “outperforming industry” rating, and raised the target price by 8.3% to HK$130.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending